OH REFERRAL FOR APPROVED MONOCLONAL ANTIBODY

(OHRH will use casirivimab/imdevimab (REGEN-COV), bamlanivimab/etesevimab, Sotrovimab, OR Bebtelovimab based on availability)
Warning: This product is no longer provided by the state. Patients/insurers will be billed for the therapy/infusion.

	Patient Name:	Patient's Age	
	Patient's DOB:	Patient's Contact Number:	
	All Questions Must	pe Answered before Order is Valid Fax Completed Form to 270-688-2275	
Has pat	ient had a positive Covid-19	test in the past ten (10) days? Yes or No	
-	For patients with mild to moderate Covid-19 symptoms and (Yes) to Positive Covid-19 test what date did the test occur?		
		(Must be within 7 days of symptom onset)	
If patie	nt has any of the following co	entraindications then monoclonal antibodies isn't a treatment option.	
•	Less than 12 years of age		
•	Weight under eighty-eight p	ounds.	
•	Require oxygen therapy due		
•		ne oxygen flow rate due to Covid-19 in those on chronicoxygen therapy.	
<u>Indicat</u>	ions for use: (Check all that	apply)	
	Age ≥ 65 years		
		> 25 or, for 12-17 years of age, BMI > 85 th percentile for age and gender based on vww.cdc.gov/growthcharts/clinical_charts.htm)	
	Pregnant		
	Chronic kidney disease		
	Diabetes		
	Immunosuppressive disease	e or immunosuppressive treatment	
	☐ Hypertension or cardiovascular disease (including congenital heart disease)		
		OPD, moderate to severe asthma, interstitial lung disease, CF, pulmonary HTN)	
	Sickle cell disease		
П	Neurodevelopmental disord	lers (i.e. CP) or other conditions that confer medical complexity (i.e. genetic or	
	-	evere congenital abnormalities)	
		cal dependence (i.e. tracheostomy, gastrostomy, or positive-pressure ventilation not	
Has the	Patient and/or Caregiver rec	eived "Fact Sheet" information in written or verbal form? Yes or No	
Has Pat	ient been informed of alterna	tives to receiving a monoclonal antibody? Yes or No	
	Patient been informed that rency Use Authorization? Yes o	nonoclonal antibodies are an unapproved drug that is authorized for use under the r No	
Provide	r Printed Name:		
Drovido	r Signaturo:		

By signing above you are authorizing the patient to receive either casirivimab/imdevimab (REGEN-COV), bamlanivimab/etesevimab, Sotrovimab, OR Bebtelovimab based on availability and indications.